RKLY - RKLY STOCK NEWS

Rockley Photonics, a leader in photonics-based health solutions, announced it will release its Q2 2022 financial results on August 11, 2022, after market close. A conference call will follow at 5:00 p.m. ET to discuss these results and the company’s outlook. Investors can access the call via telephone or through a live webcast on Rockley’s investor relations page. Rockley is known for developing advanced photonic integrated circuits and has established partnerships with Tier-1 clients across various industries to advance health monitoring and data communications.

Rockley Photonics (NYSE: RKLY) has marked a significant milestone in consumer health monitoring by shipping its VitalSpex™ Pro technology to a tier-1 consumer wearables customer. This technology enables non-invasive biomarker measurements, including alcohol and glucose levels, via wrist-worn devices. With this shipment, Rockley strengthens its partnerships with global electronics manufacturers and supports the transition towards comprehensive health monitoring. The company anticipates that the evaluation program will pave the way for future integrations, enhancing consumer wearables with advanced biosensing capabilities.

Rockley Photonics Holdings Limited (NYSE: RKLY) announces a management reshuffle as it gears up for production of its biosensing solution, following an $81.5 million private placement. Chief Financial Officer Mahesh Karanth resigns, with Chad Becker, VP of Financial Planning, stepping in as interim CFO. Ciaran Rooney is elevated to Senior VP of Corporate Development. The changes aim to align with the company's growth phase. Rockley reaffirmed its fiscal year 2022 revenue guidance provided on May 12, 2022, signaling stability amidst leadership transitions.

Rockley Photonics Holdings Limited (NYSE: RKLY) announced its inclusion in the Russell 3000® Index, effective June 27, 2022. This move follows the annual reconstitution of the Russell indexes, which captures the largest U.S. stocks by market capitalization. The Russell indexes are vital for investment managers, with approximately $12 trillion in assets benchmarked against them. CEO Andrew Rickman highlighted that this inclusion will enhance Rockley's visibility in the market and promote its innovative biosensing platform aimed at revolutionizing healthcare.

Rockley Photonics Holdings Limited (NYSE: RKLY) announces its participation in Baird's 2022 Global Consumer, Technology & Services Conference on June 6, 2022, at 8:30 a.m. ET. The company is a leader in photonics-based health monitoring and communication solutions. A live webcast of the presentation will be available on Rockley's investor relations page. Established in 2013, Rockley specializes in photonic integrated circuits and systems for various industries, aiming to make photonics as ubiquitous as micro-electronics. For more details, visit Rockley Photonics.

Rockley Photonics Holdings Limited (NYSE: RKLY) announced a partnership with Medtronic to develop next-gen wearable healthcare devices using its Bioptx™ biomarker sensing platform. The company shipped its VitalSpex Pro technology to a tier-1 customer and confirmed the Baseline band design, aiming for fourth-quarter production.

First-quarter 2022 results showed revenues of $1 million, a gross loss of $2.4 million, and a net loss of $41.8 million. The company's financial outlook for 2022 anticipates revenues between $20 million and $30 million.

Rockley Photonics Holdings Limited (NYSE: RKLY) has announced a private placement of $81.5 million in convertible senior secured notes and warrants with institutional investors. The notes will bear a cash interest rate of 9.5% and mature in 2026, with an initial conversion price of $3.08 per share. Rockley plans to use the proceeds for developing its biosensing platforms, repaying existing debt of approximately $24.9 million, and general corporate purposes. The transaction is expected to close on May 23, 2022.

Rockley Photonics has announced the success of its non-invasive biomarker sensing platform in measuring hydration levels, achieving a 99% accuracy in predicting dehydration. The company introduced the Rockley Hydration Index™, simplifying hydration assessments. Preliminary results show its wearable device can monitor hydration effectively and provide insights crucial for personal and patient hydration management. This study, overseen by qualified research staff, is a part of Rockley's ongoing efforts to enhance its biomarker sensing platform capabilities.

Rockley Photonics (NYSE: RKLY) announced the shipment of its VitalSpex™ Pro technology to a tier-1 consumer wearables customer, marking a significant advancement in non-invasive health monitoring. This technology enables the measurement of biomarkers like alcohol, glucose, and lactate, potentially transforming health outcomes. Rockley plans to begin production of its Baseline version in late 2022 and the Pro version in 2023. The company aims to enhance digital health by enabling continuous monitoring and earlier detection of chronic conditions.